Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
DXCM 
DexCom Inc (DXCM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: DXCM (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
26 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $98.59
1 Year Target Price $98.59
| 17 | Strong Buy |
| 6 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 9.13% | Avg. Invested days 41 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 32.52B USD | Price to earnings Ratio 62.35 | 1Y Target Price 98.59 |
Price to earnings Ratio 62.35 | 1Y Target Price 98.59 | ||
Volume (30-day avg) 26 | Beta 1.46 | 52 Weeks Range 57.52 - 117.19 | Updated Date 07/4/2025 |
52 Weeks Range 57.52 - 117.19 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.33 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 12.9% | Operating Margin (TTM) 12.91% |
Management Effectiveness
Return on Assets (TTM) 5.98% | Return on Equity (TTM) 23.72% |
Valuation
Trailing PE 62.35 | Forward PE 41.32 | Enterprise Value 32399275057 | Price to Sales(TTM) 7.84 |
Enterprise Value 32399275057 | Price to Sales(TTM) 7.84 | ||
Enterprise Value to Revenue 7.81 | Enterprise Value to EBITDA 33.23 | Shares Outstanding 392107008 | Shares Floating 389378433 |
Shares Outstanding 392107008 | Shares Floating 389378433 | ||
Percent Insiders 0.42 | Percent Institutions 97.1 |
Upturn AI SWOT
DexCom Inc
Company Overview
History and Background
DexCom Inc. was founded in 1999 and is headquartered in San Diego, California. The company focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for people with diabetes. DexCom has significantly advanced CGM technology, moving from sensors requiring frequent fingersticks to real-time CGM systems integrated with insulin pumps and digital health platforms.
Core Business Areas
- Continuous Glucose Monitoring (CGM) Systems: DexCom's core business is the development and sales of CGM systems, including sensors, transmitters, and receivers (or compatible smart devices). These systems provide real-time glucose data to users, helping them manage their diabetes more effectively.
Leadership and Structure
DexCom's leadership team consists of experienced executives in the medical device and technology industries. The company is structured around research and development, manufacturing, sales and marketing, and regulatory affairs, with a focus on innovation and market expansion.
Top Products and Market Share
Key Offerings
- Dexcom G7: Dexcom G7 is the latest generation CGM system that provides real-time glucose readings every five minutes. This system is designed for ease of use with a simple application and integration with other devices such as insulin pumps and smartphones. Competitors include Abbott's FreeStyle Libre 3 and Medtronic Guardian Connect.
- Dexcom G6: Dexcom G6 is a previous generation CGM system widely used for diabetes management. Market share and revenue data are not publicly segmented per product; however, G6 and G7 combined dominate the CGM market. Main competitors include Abbott's FreeStyle Libre 2 and Medtronic's Guardian Sensor 3.
Market Dynamics
Industry Overview
The diabetes care market, particularly the CGM segment, is experiencing rapid growth due to increasing diabetes prevalence, technological advancements, and a shift towards preventative care. The industry is competitive, with key players vying for market share through product innovation and partnerships.
Positioning
DexCom is a leading innovator and manufacturer of CGM systems. Its competitive advantages lie in its advanced technology, strong brand reputation, and established relationships with healthcare providers and payers.
Total Addressable Market (TAM)
The global diabetes care devices market is projected to reach hundreds of billions of USD by 2030. DexCom is well-positioned to capture a significant portion of this TAM through continued innovation and market expansion.
Upturn SWOT Analysis
Strengths
- Technological innovation
- Strong brand reputation
- Established distribution network
- High customer loyalty
- Integration with insulin pumps and digital health platforms
Weaknesses
- High product cost
- Reliance on reimbursement policies
- Competition from established medical device companies
- Sensor accuracy issues reported by some users.
Opportunities
- Expanding into new geographic markets
- Developing next-generation CGM systems
- Partnering with telehealth providers
- Integrating CGM data with AI-powered diabetes management tools.
- Expanding into non-insulin using diabetics
Threats
- Intense competition
- Technological obsolescence
- Regulatory changes
- Economic downturns
- Reimbursement cuts from payers.
Competitors and Market Share
Key Competitors
- ABT
- MDT
Competitive Landscape
DexCom competes with Abbott (ABT) and Medtronic (MDT) in the CGM market. DexCom holds advantages through technological innovation and established market presence, but faces competition from Abbott's lower-cost FreeStyle Libre system.
Growth Trajectory and Initiatives
Historical Growth: DexCom has demonstrated strong historical revenue growth driven by increasing CGM adoption and market expansion.
Future Projections: Analyst estimates project continued revenue growth for DexCom driven by product innovation, market penetration, and geographic expansion.
Recent Initiatives: Recent initiatives include the launch of Dexcom G7, partnerships with insulin pump manufacturers, and expansion into new markets.
Summary
DexCom is a strong player in the CGM market, driven by technological innovation and a robust product portfolio. Its G7 system is promising. However, it should be aware of competition from Abbot and Medtronic, as well as the potential for reimbursement cuts.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share percentages are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About DexCom Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2005-04-14 | Executive Chairman & CEO Mr. Kevin Ronald Sayer | ||
Sector Healthcare | Industry Medical Devices | Full time employees 10200 | Website https://www.dexcom.com/global |
Full time employees 10200 | Website https://www.dexcom.com/global | ||
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.